Protagenic Therapeutics, Inc.
PTIX- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001022899
In the last 90 days, Protagenic Therapeutics, Inc. insiders filed 7 open-market purchases and 0 sales; 2 institutions reported holding it in 13F filings for Q2 2026, worth $25.4K in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Protagenic Therapeutics, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Q1 2026 | Change |
|---|---|---|---|
| Holders | 12 | 4 | −8 |
| Shares | 116.5K | 66.9K | −49.6K (−42.6%) |
| Value | $150.9K | $44.4K | −$106.5K (−70.6%) |
New holders (1)
Institutions that held Protagenic Therapeutics, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| CoreCap Advisors, LLC | 100 | $68 | 0.00% |
Sold out (9)
Institutions that held Protagenic Therapeutics, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Citadel Advisors LLC | 23,311 | $30.3K |
| Geode Capital Management, LLC | 12,182 | $15.8K |
| Raymond James Financial Inc | 10,001 | $13.0K |
| Tower Research Capital LLC (TRC) | 3,045 | $3.96K |
| Advisor Group Holdings, Inc. | 49 | $64 |
| Bank of America Corp | 17 | $22 |
| Morgan Stanley | 2 | $2 |
| Harbor Investment Advisory, LLC | 1 | $1 |
| CWM, LLC | 1 | $0 |